HC Wainwright & Co. Reiterates Buy on Atara Biotherapeutics, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its 'Buy' rating on Atara Biotherapeutics (NASDAQ:ATRA) and maintained its price target of $28.
September 26, 2023 | 10:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atara Biotherapeutics' stock may see positive movement as HC Wainwright & Co. has reiterated its 'Buy' rating and maintained its price target of $28.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of a 'Buy' rating and maintenance of a $28 price target by HC Wainwright & Co. indicates their continued confidence in Atara Biotherapeutics, which could positively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100